How much does Wegovy cost in 2026? Every price pathway explained

The retail price vs. what you actually pay

Wegovy's list price at a retail pharmacy without any program is approximately $1,350 a month — close to $16,000 a year. That number gets cited a lot and is almost universally not what people actually pay. It represents what you'd pay if you walked into a pharmacy, handed over a prescription, and had no insurance, no NovoCare program, and no coupon. For most women who proactively seek Wegovy, the real price is substantially lower.

Understanding which pathway applies to you takes about ten minutes and determines whether Wegovy costs you $25 a month or $1,350.

The cheapest pathway: commercial insurance + NovoCare savings card

If your commercial health insurance covers Wegovy and you enroll in the NovoCare savings card, your monthly out-of-pocket is capped at $25 a month. This is the most favorable Wegovy price available, and it's accessible to anyone with qualifying commercial insurance (not Medicare, Medicaid, or government insurance).

Getting to the savings card requires two things first: insurance coverage for Wegovy (which requires prior authorization, the right BMI, and often documented comorbidities), and a pharmacy in the NovoCare network. The $25 cap is a manufacturer subsidy that doesn't count toward your deductible in many plans — worth confirming with your insurer.

• Eligibility: commercial insurance with Wegovy covered; not Medicare, Medicaid, or CHIP.
• How to enroll: through NovoCare's website or at the point of sale at a participating pharmacy.
• If you're denied coverage: appeal with a physician letter citing BMI, comorbidities, and previous lifestyle treatment. Many initial denials reverse on the first appeal.
• Annual maximums: check whether the savings card has an annual cap or monthly limit, as terms can change.

Without insurance: NovoCare self-pay from $149 (pill) or $199 (pen)

For women without insurance coverage for Wegovy, Novo Nordisk's NovoCare self-pay program is the best brand-name option, and it now has two formats. The Wegovy pill costs $149 a month at the 1.5 mg starting dose, $199 at 4 mg, and $299 at the 9 mg and 25 mg maintenance doses. The pen is $199 a month for your first two fills as a new patient (an offer running through December 31, 2026), then $349 a month at the standard 0.25 to 2.4 mg doses or $399 at the 7.2 mg HD strength. Both are FDA-approved Wegovy, shipped from NovoCare Pharmacy or picked up at a retail pharmacy at the same price, and the ladder applies identically whether you're uninsured or your plan simply won't cover the drug.

At $299 a month for the top pill doses, that's roughly $3,588 a year; the pen at $349 ongoing is about $4,188 — a real expense either way, but a fraction of the retail pharmacy price, through an official Novo Nordisk program rather than a third-party coupon. Budget for the maintenance dose, not the starting one.

GoodRx: it now mirrors Novo's cash price

GoodRx used to run its own Wegovy coupon in the $300 to $500 range. That's gone: GoodRx now surfaces Novo Nordisk's self-pay cash price at more than 70,000 pharmacies — $149 to $299 for the pill by dose, $199 for the first two pen fills then $349 to $399. It won't beat NovoCare, but it gets you the same price at your usual pharmacy without a mail-order shipment. It can't be combined with insurance or the $25 savings card.

One trap: a plain GoodRx retail coupon on Wegovy, outside the Novo partnership, still lands near list price. Make sure the quote you're looking at says it's the Novo Nordisk cash price before you fill.

Compounded semaglutide: cheaper than Wegovy, not FDA-approved Wegovy

Compounded semaglutide through a telehealth provider — Fridays, Mochi Health, Henry Meds, and others — starts around $150 a month all-in for the starter dose. This is the same active molecule as Wegovy, produced by a 503A compounding pharmacy. It is not FDA-approved Wegovy; it lacks Novo Nordisk's manufacturing oversight and finished-product approval.

For women who want the lowest possible monthly cost and are comfortable with compounded medication and its legal framework, this is the cheapest semaglutide available. For women who want brand-name, FDA-approved Wegovy specifically, the NovoCare self-pay program is the better-value brand pathway.

Medicare and Wegovy: the $50 GLP-1 Bridge

Medicare long excluded weight-loss drugs from Part D, which is also why the $25 savings card can't be used with Medicare. That changed on July 1, 2026, when CMS launched the Medicare GLP-1 Bridge: eligible Part D and Medicare Advantage members can get any dose of Wegovy, pen or pill, for a flat $50 a month through December 31, 2027. Eligibility is BMI-based — 35 or higher; 30 or higher with heart failure, uncontrolled hypertension or stage 3a+ kidney disease; or 27 or higher with prediabetes or a history of heart attack, stroke or peripheral artery disease — and the $50 doesn't count toward your Part D out-of-pocket cap. Separately, some Part D plans already covered Wegovy under its cardiovascular indication after the SELECT trial; if you have established cardiovascular disease, compare that copay against the flat $50. The Wegovy savings guide walks through the enrollment steps.

Annual cost by pathway

• Commercial insurance + NovoCare savings card ($25/mo): $300/year — lowest possible pathway.
• Medicare GLP-1 Bridge ($50/mo): $600/year.
• NovoCare self-pay pill ($149–$299/mo by dose): ~$1,788–$3,588/year; pen at the $349–$399/mo maintenance rate: ~$4,188–$4,788/year.
• GoodRx (same Novo cash price, $149–$399/mo): ~$1,788–$4,788/year.
• Compounded semaglutide, Fridays ($150–$249/mo): ~$1,800–$2,988/year depending on dose.
• Mochi Health all-in (~$178/mo): ~$2,136/year.
• Retail, no discount (~$1,350/mo): ~$16,200/year.